US2013012586A1PendingUtilityA1
Methods of Treating Fragile X Syndrome
Est. expiryNov 22, 2026(~0.3 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 25/22A61P 25/18A61P 25/00A61P 25/08A61K 31/195A61K 31/197A61K 31/215A61K 31/428A61P 15/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.
Claims
exact text as granted — not AI-modified1 . A method of improving at least one of motivation, calmness, class participation, ability to tolerate stress and sleep patterns in a human having fragile X syndrome, comprising the step of orally administering to the human a composition that includes a therapeutically effective amount of at least one GABA(B) agonist.
2 . The method of claim 1 , wherein the GABA(B) agonist is administered to the human in a dose of about 0.001 mg/kg/day to about 5 mg/kg/day.Join the waitlist — get patent alerts
Track US2013012586A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.